Novo Nordisk A/S (NYSE:NVO) Shares Up 1.2% - Time to Buy?

Key Points

• NICE recommended Wegovy to reduce heart-attack and stroke risk, potentially expanding NHS access to roughly 1.2 million people — a material demand and access win for Novo Nordisk.
• Eli Lilly won FDA approval for oral GLP‑1 Foundayo, creating renewed competitive pressure and multi‑billion sales forecasts, while Novo is countering with a subscription/pricing plan, telehealth partnerships and cross‑trial data claiming oral Wegovy outperforms Lilly’s candidate.
• The stock was up 1.2% intraday; analysts hold a consensus “Hold” rating with a $65.56 average price target, and Novo reported strong recent results (market cap ~$165B, P/E ~10.6) alongside a newly declared dividend.

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) shot up 1.2% during mid-day trading on Thursday . The stock traded as high as $36.98 and last traded at $36.9220. 14,564,570 shares changed hands during trading, a decline of 39% from the average session volume of 24,040,957 shares. The stock had previously closed at $36.48.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: UK regulator (NICE) recommended Wegovy to reduce heart‑attack and stroke risk, potentially expanding NHS access to ~1.2 million people — a material demand/access win for Novo. British drug-cost watchdog recommends use of Novo's Wegovy to lower heart risks
• Positive Sentiment: Novo launched a Wegovy subscription/pricing program and partnerships with telehealth providers to lower effective monthly cost for self‑pay patients — a defensive commercial move to protect share and adherence. NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
• Positive Sentiment: Company released a cross‑trial indirect comparison (ORION study) saying oral Wegovy showed greater mean weight loss and lower discontinuation vs Lilly’s oral candidate — a messaging/data point Novo can use to blunt competitive headlines. Novo Nordisk says Wegovy pill outperforms Lilly's oral GLP-1 in cross-trial comparison
• Positive Sentiment: Pipeline progress: Novo is advancing next‑gen programs (triple agonist UBT251 in early global studies) — supports longer‑term growth optionality beyond current GLP‑1 dynamics. Novo Nordisk Triple Agonist Progress Spurs Questions On Valuation Gap
• Neutral Sentiment: Market reaction shows resilience: early trading held firm/edged up as investors appear to have partly priced in competitive risk and are focusing on access and pricing initiatives. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: Eli Lilly (LLY) won FDA approval for its oral GLP‑1 (Foundayo/orforglipron) with a commercial launch imminent and forecasts for multi‑billion dollar sales — intensifies competition and could erode Novo’s oral market leadership and pricing power. Wall Street sees multi-billion dollar debut for Lilly's obesity pill despite Novo lead
• Negative Sentiment: Multiple outlets report Lilly’s approval and launch (Foundayo) will put fresh pressure on Novo’s Wegovy franchise and has already boosted Lilly shares — a near‑term headwind for NVO revenue growth expectations. Eli Lilly wins FDA approval for weight loss pill, tees up Novo rivalry
• Negative Sentiment: Policy risk: report that the U.S. administration is preparing up to 100% tariffs on branded drugs for companies not striking price deals could hit U.S. pricing/sales if applied broadly — an added macro/regulatory downside for major pharma exporters including Novo. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Some analyst commentary and downgrades have appeared amid the intensified competitive backdrop, which can amplify negative sentiment around near‑term valuation and guidance risk. Novo Nordisk: I Admit That I Was Really Wrong (Downgrade)

Analyst Ratings Changes

Several research analysts recently weighed in on NVO shares. JPMorgan Chase & Co. reaffirmed a "neutral" rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a "hold" rating in a report on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, February 23rd. Sanford C. Bernstein began coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They issued an "outperform" rating and a $175.00 price objective on the stock. Finally, Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Hold" and a consensus price target of $65.56.

Novo Nordisk A/S Trading Up 1.2%

The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market capitalization of $164.86 billion, a P/E ratio of 10.64, a price-to-earnings-growth ratio of 8.69 and a beta of 0.73. The firm has a 50 day moving average price of $44.44 and a two-hundred day moving average price of $50.07.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The company had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. This represents a yield of 723.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S's payout ratio is presently 52.74%.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Martin Capital Partners LLC grew its stake in Novo Nordisk A/S by 53.8% during the 3rd quarter. Martin Capital Partners LLC now owns 117,577 shares of the company's stock valued at $6,524,000 after acquiring an additional 41,129 shares in the last quarter. Smith Chas P & Associates PA Cpas lifted its position in shares of Novo Nordisk A/S by 105.3% in the third quarter. Smith Chas P & Associates PA Cpas now owns 405,425 shares of the company's stock worth $22,497,000 after purchasing an additional 207,959 shares in the last quarter. Clifford Swan Investment Counsel LLC boosted its holdings in shares of Novo Nordisk A/S by 13.7% during the third quarter. Clifford Swan Investment Counsel LLC now owns 311,168 shares of the company's stock worth $17,267,000 after purchasing an additional 37,453 shares during the period. Markel Group Inc. grew its position in Novo Nordisk A/S by 4.9% during the third quarter. Markel Group Inc. now owns 2,368,649 shares of the company's stock valued at $131,436,000 after purchasing an additional 110,061 shares in the last quarter. Finally, Cantor Fitzgerald Investment Advisors L.P. purchased a new position in Novo Nordisk A/S during the third quarter valued at approximately $1,294,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.